Most Read Articles
Roshini Claire Anthony, 02 Feb 2018

The use of weight loss medications for at least 1 year did little to improve cardiometabolic risk factors in obese adults, according to a systematic review and meta-analysis.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
26 Feb 2019
Oral fluoxetine confers beneficial effects in the management of adult and adolescent amblyopia, suggests a recent study.
19 Feb 2019
Preprandial administration of metformin successfully and safely reduces postprandial plasma triglyceride levels, a new study has shown.

Concomitant csDMARD use leads to lower bDMARD discontinuation in RA patients

10 Aug 2019

Concomitant use of conventional synthetic disease-modifying antirheumatic drug (csDMARD) results in a significantly lower risk for discontinuation of biologic (b)DMARD because of adverse events (AEs) among patients with rheumatoid arthritis (RA), according to a recent study.

In addition, neither methotrexate (MTX) route of administration nor dose significantly predicted bDMARD durability.

A total of 814 patients were included, among whom 153 (18.8 percent) received bDMARD monotherapy and 661 (81.2 percent) combination csDMARD/bDMARD therapy. Of the patients, 38.7 percent discontinued bDMARD over a mean follow-up of 1.9 years.

Multivariate analysis revealed a nonsignificant trend toward lower discontinuation for the combination therapy vs monotherapy for any reason (hazard ratio [HR] ,0.76, 95 percent CI, 0.55–1.05) and owing to ineffectiveness/AE (HR, 0.73, 0.50–1.06). Moreover, the risk of bDMARD discontinuation due to AE was significantly lower among patients taking the combination therapy (HR, 0.43, 0.24–0.76).

The secondary analysis showed no statistically significant relationship between MTX dose or route of administration and bDMARD durability.

The study enrolled patients from the Ontario Best Practices Research Initiative who initiated bDMARD therapy and had ≥1 follow-up assessment. Multivariate Cox regression was used to assess the effect of concomitant csDMARD use and MTX route of administration on bDMARD discontinuation due to (1) any reason, (2) ineffectiveness, (3) AEs, or (4) both ineffectiveness and AEs.

“Prior studies have suggested that concurrent csDMARD therapy enhances the efficacy of bDMARD,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 02 Feb 2018

The use of weight loss medications for at least 1 year did little to improve cardiometabolic risk factors in obese adults, according to a systematic review and meta-analysis.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
26 Feb 2019
Oral fluoxetine confers beneficial effects in the management of adult and adolescent amblyopia, suggests a recent study.
19 Feb 2019
Preprandial administration of metformin successfully and safely reduces postprandial plasma triglyceride levels, a new study has shown.